Ontogeny of hepatic Organic Cation Transporter-1 in rat and human .

The organic cation transporter-1 (OCT1) mediates hepatic uptake of cationic endogenous compounds and xenobiotics. To date, limited information exists on how Oct1/OCT1 functionally develops with age in rat and human livers) and how this would affect pharmacokinetics of OCT substrates in children or juvenile animals. The functional ontogeny of rOct/hOCT was profiled in suspended rat (2-57 days old) and human hepatocytes (paediatric liver tissue donors: age 2-12 months) by determining uptake clearance of 4-[4-(dimethylamino)styryl]-N-methylpyridinium iodide (ASP + ) as a known rOct/hOCT probe substrate. mRNA expression was determined in rat liver tissue corresponding to rat ages used in the functional studies, while hOCT1 mRNA expressions were determined in the same hepatocyte batches as used for uptake studies. Maturation of rOct/hOCT activity and expression were evaluated by comparing values obtained at the various ages to the adult values. Relative to adult values (at 8 weeks), ASP + uptake clearance in suspended rat hepatocytes aged 0, 1, 2, 3, 4, 5 and 6 weeks reached 26, 29, 33, 37, 72, 63 and 71%, respectively. Hepatic Oct1 mRNA expression was consistent with Oct activity (correlation coefficient of 0.92). In human hepatocytes, OCT1 activity was age-dependent and also correlated with mRNA levels (correlation coefficient of 0.88). These data show thatOct1/OCT1 activities and expression mature gradually in rat/human liver, thereby mirroring the expression pattern of Organic Anion Transporting Polypeptide (Oatp1b2) in rat. These high-resolution transporter ontogeny profiles will allow for more accurate prediction of the pharmacokinetics of OCT1/Oct1 substrates in paediatric populations and juvenile animals. Significance Statement Organic Cation Transporter-1 (OCT1) represents a major drug uptake transporter in human liver. This study provides high resolution data regarding the age-dependent function of OCT1 in the liver, based on in vitro experiments with rat and human hepatocytes obtained from donors between birth and adulthood. These ontogeny profiles will inform improved age-specific physiologically-based pharmacokinetic (PBPK) models for OCT1 drug substrates in neonates, infants, children and adults.